Bolt Biotherapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Bolt Biotherapeutics, Inc. (BOLT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -1.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-12
- Bolt Biotherapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -1.90%.
- Bolt Biotherapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -2.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | -1.90% 10-K · filed 2026-03-12 |
| 2024-12-31 | -2.90% 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |